Recent News
Orphagen Pharmaceuticals to present preclinical data for OR-449 at the Endocrine Society’s 2021 Annual Meeting
Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that data from its preclinical program to develop...
ORPHAGEN PHARMACEUTICALS AWARDED SBIR PHASE II GRANT TO INVESTIGATE RETINOIC TARGETS FOR MALE CONTRACEPTIVES
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has awarded the company $1.8 million under the Small Business Innovation Research (SBIR)...
Orphagen Pharmaceuticals and the Pharmaceutical Division of Japan Tobacco Enter into a Collaborative Agreement
San Diego, June 1, 2018 – Orphagen Pharmaceuticals, a privately held pharmaceutical company, announced today that it has entered into a collaborative agreement with the pharmaceutical division of Japan Tobacco Inc. (JT) to discover, develop and commercialize drugs...
Orphagen Pharmaceuticals Awarded Additional US Patent for Modulators of Orphan Nuclear Receptor ROR-gamma
San Diego, June 1, 2018 – Orphagen Pharmaceuticals, a privately held pharmaceutical company, announced today that it has been awarded US patent 9,657,053 for the use of small molecule ligands to inhibit retinoid-related orphan receptor gamma...
ORPHAGEN PARTNER, JAPAN TOBACCO, INITIATES A PHASE I CLINICAL TRIAL OF A NOVEL SMALL MOLECULE THERAPEUTIC FOR AUTOIMMUNE AND ALLERGIC DISEASES
Orphagen Pharmaceuticals, Inc., a privately held company, announced today that its partner, Japan Tobacco Inc. (“JT”), has entered Phase I clinical trials with an oral small molecule, JTE-451, for treatment of autoimmune and allergic diseases. This is a major...